Histology
Carcinoma of Unknown Primary
CI-CAN-00002109Explore in graph →
4,156 active trials54 approved drugs532 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00002109Explore in graph →
Clinical trials
14,232 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,893)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04193293 | A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer | terminated | Phase 1 / Phase 2 | 2 | SecuraBioINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT01093183 | Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer | terminated | Phase 1 / Phase 2 | 25 | University of NebraskaOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT01755650 |
| Phase 0 of 18F FPM Using PET/CT in Patients With a Variety of Malignancies |
| terminated |
| Early Phase 1 |
| 6 |
| Peter MacCallum Cancer Centre, AustraliaOTHER |
| 1 |
| Sep 13, 2023 |
| clinicaltrials |
| NCT03912818 | Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer | terminated | Phase 2 | 7 | Stanford UniversityOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT02524275 | Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | terminated | Phase 2 | 14 | University of NebraskaOTHER | 1 | Sep 8, 2023 | clinicaltrials |
| NCT04441099 | NBE-002 in Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 12 | NBE-Therapeutics AGINDUSTRY | 1 | Sep 7, 2023 | clinicaltrials |
| NCT02112552 | Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer | terminated | Phase 2 | 4 | Albert Einstein College of MedicineOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT03963414 | A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC | terminated | Phase 1 | 1 | University of NebraskaOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT04720664 | Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer(OASIS) | terminated | Phase 2 | 11 | Georgetown UniversityOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT04271254 | PET/MR Characterization of Renal Cell Carcinomas | terminated | N/A | 5 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 24, 2023 | clinicaltrials |
| NCT05027867 | KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer | terminated | Phase 2 | 3 | Kartos Therapeutics, Inc.INDUSTRY | 7 | Aug 16, 2023 | clinicaltrials |
| NCT04185311 | Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted | terminated | Phase 1 | 6 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT01712815 | PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer | terminated | N/A | 12 | University of Southern CaliforniaOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT04750239 | Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer | terminated | Phase 1 / Phase 2 | 3 | Y-mAbs TherapeuticsINDUSTRY | 1 | Aug 14, 2023 | clinicaltrials |
| NCT04644315 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors(ALpha-T) | terminated | Phase 2 | 1 | Hoffmann-La RocheINDUSTRY | 1 | Aug 7, 2023 | clinicaltrials |
| NCT00707655 | Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy | terminated | Phase 1 / Phase 2 | 8 | GenmabINDUSTRY | 3 | Aug 3, 2023 | clinicaltrials |
| NCT03024996 | A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy(IMmotion010) | terminated | Phase 3 | 778 | Hoffmann-La RocheINDUSTRY | 28 | Aug 3, 2023 | clinicaltrials |
| NCT04639245 | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT02059265 | Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer | terminated | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Aug 1, 2023 | clinicaltrials |
| NCT03576131 | GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 48 | GenmabINDUSTRY | 3 | Aug 1, 2023 | clinicaltrials |
| NCT04424641 | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 48 | GenmabINDUSTRY | 4 | Jul 25, 2023 | clinicaltrials |
| NCT04688749 | Use of Electrical Impedance Spectroscopy (EIS) for Early Diagnosis of Skin Damage(DermaSense) | terminated | — | 50 | Aristotle University Of ThessalonikiOTHER | 1 | Jul 25, 2023 | clinicaltrials |
| NCT05584332 | A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females | terminated | Phase 3 | 3,131 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Jul 21, 2023 | clinicaltrials |
| NCT02592707 | Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs | terminated | Phase 1 / Phase 2 | 40 | IpsenINDUSTRY | 8 | Jul 19, 2023 | clinicaltrials |
| NCT03740100 | Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations(HNSCC) | terminated | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT03970616 | A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma(DEDUCTIVE) | terminated | Phase 1 / Phase 2 | 27 | AVEO Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 12, 2023 | clinicaltrials |
| NCT02530437 | Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer | terminated | Phase 1 / Phase 2 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 10, 2023 | clinicaltrials |
| NCT03591965 | Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects | terminated | Phase 2 | 73 | Antengene Therapeutics LimitedINDUSTRY | 3 | Jul 10, 2023 | clinicaltrials |
| NCT00303628 | Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer | terminated | Phase 3 | 355 | ECOG-ACRIN Cancer Research GroupNETWORK | 4 | Jul 6, 2023 | clinicaltrials |
| NCT03986593 | Cryoablation of Bone Metastases From Endocrine Tumors | terminated | N/A | 17 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT02031536 | Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery | terminated | Phase 2 | 2 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT01824823 | Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence | terminated | Phase 2 | 3 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 28, 2023 | clinicaltrials |
| NCT02067741 | CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer | terminated | Phase 2 | 29 | Swiss Cancer InstituteOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT02488629 | Study of SCB01A in Patient With Head and Neck Cancer | terminated | Phase 2 | 5 | SynCore Biotechnology Co., Ltd.INDUSTRY | 1 | Jun 27, 2023 | clinicaltrials |
| NCT04543955 | Telotristat With Lutathera in Neuroendocrine Tumors | terminated | Phase 2 | 1 | Lowell Anthony, MDOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT01992861 | MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer | terminated | — | 51 | University of WashingtonOTHER | 3 | Jun 26, 2023 | clinicaltrials |
| NCT05153408 | (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC | terminated | Phase 1 | 20 | Blueprint Medicines CorporationINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT03522584 | Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 6 | University of WashingtonOTHER | 1 | Jun 12, 2023 | clinicaltrials |
| NCT03824704 | A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | terminated | Phase 2 | 1 | pharmaand GmbHINDUSTRY | 1 | Jun 12, 2023 | clinicaltrials |
| NCT03827850 | FGFR Inhibitor in FGFR Dysregulated Cancer(FIND) | terminated | Phase 2 | 22 | Lung Cancer Group CologneOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT04305236 | Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer | terminated | Phase 2 | 1 | University of California, IrvineOTHER | 1 | Jun 6, 2023 | clinicaltrials |
| NCT03637803 | Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors | terminated | Phase 1 / Phase 2 | 63 | 4D pharma plcINDUSTRY | 1 | Jun 1, 2023 | clinicaltrials |
| NCT05375604 | A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From EIther Primary Gastric Cancer or Colorectal Cancer (CRC) | terminated | Phase 1 | 9 | Codiak BioSciencesINDUSTRY | 1 | Jun 1, 2023 | clinicaltrials |
| NCT03553212 | Twice High Dose External Beam Radiotherapy by Image-guided Tomotherapy for Organ-confined Prostate Cancer Treatment Emulating High Dose Radiation (HDR) Brachytherapy(THRIP) | terminated | N/A | 2 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | May 30, 2023 | clinicaltrials |
| NCT00946712 | S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer | terminated | Phase 3 | 1,333 | SWOG Cancer Research NetworkNETWORK | 2 | May 23, 2023 | clinicaltrials |
| NCT00227617 | Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors | terminated | Phase 2 / Phase 3 | 36 | University of California, San FranciscoOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT03535675 | Muscadine Plus (MPX) In Men With Prostate Cancer | terminated | Phase 3 | 59 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT04843319 | To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer(VERU-100) | terminated | Phase 1 / Phase 2 | 24 | Veru Inc.INDUSTRY | 1 | May 19, 2023 | clinicaltrials |
| NCT03515603 | Endocrine Outcome of Surgery for Pituitary Adenoma | terminated | N/A | 36 | University of UlmOTHER | 1 | May 17, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Sep 21, 2023source: clinicaltrials